<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440245</url>
  </required_header>
  <id_info>
    <org_study_id>Bio-REB 06-231</org_study_id>
    <nct_id>NCT00440245</nct_id>
  </id_info>
  <brief_title>Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Bronchoprotection of Salbutamol in Asthma and COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate potential differences in how two puffs of salbutamol protects
      airway smooth muscle from contracting in people with asthma and chronic obstructive pulmonary
      disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In asthma, the administration (inhalation) of a selective β2 receptor agonist (e.g.
      salbutamol), prior to methacholine challenge has been shown to shift the dose response curve
      to the right and &quot;bronchoprotect&quot; the airway against airway smooth muscle contraction. The
      extent of β2 receptor agonist bronchoprotection in COPD is unknown.

      Airway hyperresponsiveness (AHR) to direct acting agents such as histamine and methacholine
      is a feature of both asthma and COPD. In asthma, the abnormality leading to AHR is believed
      to be due to changes in airway smooth muscle (e.g. hypertrophy, hyperplasia, contractile
      apparatus) whereas in COPD the AHR is likely due to structural or geometric changes.

      The investigators hypothesize that the bronchoprotection afforded by salbutamol against
      methacholine challenge will be greater in asthma than in COPD due to differences in
      underlying airway abnormalities.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>methacholine PC20 dose shift</measure>
    <time_frame>one hour</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Asthma</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>salbutamol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salbutamol</intervention_name>
    <description>200 micrograms salbutamol from MDI</description>
    <arm_group_label>salbutamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  asthma or COPD

        Exclusion Criteria:

          -  asthma and COPD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Davis, PhD</last_name>
    <phone>306-844-1444</phone>
    <email>beth.davis@usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Davis, PhD</last_name>
      <phone>306-844-1444</phone>
      <email>beth.davis@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Donald Cockcroft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2007</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

